Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR Accessibility StatementSkip Navigation SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.(Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsulesshowed higher treatment persistence compared ...